Revolution Medicines, Inc. Share Price
NASDAQ: RVMD | Large CapRevolution Medicines, Inc. Stock Performance
Open $219.87 | Prev. Close $221.22 | Circuit Range N/A |
Day Range $205.92 - $219.87 | Year Range $37.60 - $220.29 | Volume 94,536 |
Average Traded $209.26 |
Revolution Medicines, Inc. Share Price Today
As of 29 August 2026, Revolution Medicines, Inc.'s share price is $208.02. The stock opened at $219.87, compared to its previous close of $221.22. During today's trading session, Revolution Medicines, Inc.'s share price traded between $205.92 and $219.87, with an average price of $212.89. Over the past 52 weeks, the stock has recorded a high of $220.29 and a low of $37.60. In terms of performance, Revolution Medicines, Inc.'s share price has risen by 103.76% over the last six months and is up 447.85% on a year-on-year basis.
Revolution Medicines, Inc. Share Price Chart
Revolution Medicines, Inc. Stock Fundamentals & Key Indicators
Market Cap $39.55B | PE Ratio (TTM) -34.96 | Dividend Yield N/A |
EPS (TTM) $-5.95 | Revenue (TTM) N/A | Return On Equity (TTM) -69.35% |
Profit Margin N/A | Debt to Equity 0.18 | Quarterly Earnings Growth YoY -83.97% |
Revolution Medicines, Inc. Quarterly Profit & Loss
All figures in USD
Revolution Medicines, Inc. Annual Profit & Loss
All figures in USD
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $185.69 | $222.00 | +18.34% |
Jul 2026 | $186.56 | $187.59 | +0.24% |
Jun 2026 | $159.05 | $187.15 | +18.76% |
May 2026 | $141.50 | $157.59 | +9.28% |
Apr 2026 | $98.32 | $144.21 | +48.39% |
Mar 2026 | $100.93 | $97.18 | -4.81% |
Feb 2026 | $96.25 | $102.09 | +5.39% |
Jan 2026 | $79.83 | $96.87 | +21.60% |
Dec 2025 | $77.20 | $79.66 | +2.38% |
Nov 2025 | $58.93 | $77.81 | +32.28% |
Oct 2025 | $46.93 | $58.82 | +25.93% |
Sep 2025 | $38.33 | $46.71 | +23.02% |
RVMD Share Price FAQs
What is Revolution Medicines, Inc. share price today?
What is the 52 week high and 52 week low of Revolution Medicines, Inc. stock?
What is RVMD's market capitalisation today?
What is RVMD's net income for the last quarter?
What is the 5 year returns of RVMD?
What is the high & low stock price of RVMD today?
Can I buy RVMD shares in India?